Adherence to National Guidelines on Cervical Screening: A Population-Based Evaluation from a Statewide Registry.
Journal
Journal of the National Cancer Institute
ISSN: 1460-2105
Titre abrégé: J Natl Cancer Inst
Pays: United States
ID NLM: 7503089
Informations de publication
Date de publication:
31 Aug 2021
31 Aug 2021
Historique:
received:
20
09
2020
revised:
05
04
2021
accepted:
25
08
2021
entrez:
31
8
2021
pubmed:
1
9
2021
medline:
1
9
2021
Statut:
aheadofprint
Résumé
In 2012, national recommendations for cervical-cancer screening of women aged 30-64 years were quinquennial human papillomavirus and cytology co-testing or triennial cytology. Data from a state-wide surveillance program in New Mexico demonstrated 65.2% (95% confidence interval [95%CI]= 64.6%% to 65.7%) of women screened in 2019 had negative co-test within the last 3 years. Percentages of women screened in 2013, 2016, and 2019 with a prior negative co-test more than 5 and up to 7 years ago were 2.6% (95% CI = 2.2% to 2.9%), 2.1% (95% CI = 1.9% to 2.2%), and 6.5% (95% CI = 6.2% to 6.8%), respectively (2-sided P trend<.001). Percentages of women screened in 2013, 2016, and 2019 with a prior negative cytology more than 5 and up to 7 years ago were 3.8% (95% CI = 3.7% to 3.9%), 9.0% (95% CI = 8.7% to 9.3%), and 14.9% (95% CI = 14.4% to 15.4%), respectively (2-sided P trend<.001). Thus, in 2019, only 12.7% (95% CI = 12.4% to 13.1%) of the 30,215 women aged 30-64 years underwent co-testing and 27.7% (95% CI = 27.1% to 28.3%) of the 18,733 underwent cytology at the recommended interval. The observed under- and over-screening could result in increases in cervical-cancer incidence and harms and costs, respectively.
Identifiants
pubmed: 34463763
pii: 6360464
doi: 10.1093/jnci/djab173
pmc: PMC9002271
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : P30 CA118100
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI113187
Pays : United States
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press.
Références
N Engl J Med. 2009 Apr 2;360(14):1385-94
pubmed: 19339719
Cancer Epidemiol Biomarkers Prev. 2014 May;23(5):765-73
pubmed: 24302677
JAMA Intern Med. 2013 May 27;173(10):922-4
pubmed: 23568334
Obstet Gynecol. 2004 Feb;103(2):304-9
pubmed: 14754700
J Womens Health (Larchmt). 2016 May;25(5):422-7
pubmed: 27096534
Ann Intern Med. 2012 Jun 19;156(12):880-91, W312
pubmed: 22711081
J Natl Cancer Inst. 2014 Jul 18;106(8):
pubmed: 25038467
Prev Med. 2013 Nov;57(5):641-5
pubmed: 24012831
Lancet. 2014 Feb 8;383(9916):524-32
pubmed: 24192252
Prev Med. 2020 Feb 3;133:106014
pubmed: 32027912
JAMA. 2018 Aug 21;320(7):674-686
pubmed: 30140884
Am J Clin Pathol. 2012 Apr;137(4):516-42
pubmed: 22431528
Prev Med. 2017 Jul;100:243-247
pubmed: 28502575
Am J Prev Med. 2015 Dec;49(6):e99-107
pubmed: 26141914